ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 656,48
-0,10%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) Actualités

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GLUE
DateHeureSourceTitreSymboleSociété
30/05/202413h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Leadership Team PromotionsNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseNASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202422h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/05/202422h01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202413h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
02/05/202422h01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
14/03/202412h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/03/202412h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/01/202413h15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
04/01/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/11/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/11/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202316h00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/10/202322h30GlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
18/08/202322h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/08/202323h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
10/08/202313h15GlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/07/202313h30GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/06/202322h43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GLUEMonte Rosa Therapeutics Inc
14/06/202322h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202322h30GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Upcoming Investor and Industry ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
23/05/202313h30GlobeNewswire Inc.Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GLUE

Dernières Valeurs Consultées

COIN
ADXXUST
AnonyDoxx
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés